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The Centers for Disease Control and Prevention provides biomonitoring data in the United States as part of the National Health
and Nutrition Examination Survey (NHANES). Recently, Statistics Canada initiated a similar survey --- the Canadian Health
Measures Survey (CHMS). Comparison of US and Canadian biomonitoring data can generate hypotheses regarding human
exposures from environmental media and consumer products. To ensure that such comparisons are scientiﬁcally meaningful, it
is essential to ﬁrst evaluate aspects of the surveys’ methods that can impact comparability of data. We examined CHMS and
NHANES methodologies, using bisphenol A (BPA) as a case study, to evaluate whether survey differences exist that would
hinder our ability to compare chemical concentrations between countries. We explored methods associated with participant
selection, urine sampling, and analytical methods. BPA intakes were also estimated to address body weight differences between
countries. Differences in survey methods were identiﬁed but are unlikely to have substantial impacts on inter-survey
comparisons of BPA intakes. BPA intakes for both countries are below health-based guidance values set by the US, Canada and
the European Food Safety Authority. We recommend that before comparing biomonitoring data between surveys, a thorough
review of methodologic aspects that might impact biomonitoring results be conducted.
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INTRODUCTION
The National Center for Environmental Health (NCEH) at the
Centers for Disease Control and Prevention (CDC) provides data
on an increasing number of chemicals in blood and urine for a
nationally representative sample of the US population as part of
the National Health and Nutrition Examination Survey (NHANES).
Recently, Statistics Canada initiated a similar nationally represen-
tative survey called the Canadian Health Measures Survey (CHMS)
and released data from its ﬁrst collection cycle (cycle 1, 2007--
2009).
1,2 Comparisons of population exposures across countries
can be highly informative and can generate hypotheses regarding
differences and similarities in exposures from various sources such
as air, water, soil, food, and consumer products. To ensure that
such comparisons are scientiﬁcally meaningful, it is essential to
evaluate aspects of the surveys’ methods that have the potential
to impact data comparability. These include differences in urine
and blood collection and handling, analytical approaches, and
data analysis as well as differences in population characteristics.
For this paper, we analyzed spot urinary bisphenol A (BPA) data
from NHANES and CHMS to highlight important methodological
issues that should be reviewed before comparing population
exposures using these data sets. This is the ﬁrst time that
nationally representative data for Canada have been released,
permitting comparison with US population-based data. BPA was
selected because it is the subject of scientiﬁc and regulatory
interest in both countries, there are sufﬁcient data to assess
intakes based on urinary concentrations, and there may be
sufﬁcient data to begin to examine the effect of temporal changes
on our ability to compare intakes between surveys.
To determine whether population estimates differ between
surveys, we ﬁrst describe spot urinary BPA concentrations for
Canada (CHMS 2007--2009) and the US (NHANES 2007--2008) and
estimate intakes (as dose in units of nanograms per kilogram-day)
based on those data. We then explore the possible reasons for the
differences between the US and Canadian estimates by examining
the survey methodologies. We focus on population characteristics,
procedures related to collection and handling of urine samples,
analytical methods, and data reporting. As both CHMS and
NHANES will continue to generate population-based biomonitor-
ing data for many chemicals, this review is timely and important
for researchers seeking to compare data across countries.
METHODS
Estimation of Daily BPA Intakes
The method for estimating daily intake for individuals with spot urinary
BPA data from NHANES has been described previously
3,4; a similar method
was used to estimate daily intakes for the 2007- -2008 NHANES (http://
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2007--2009 CHMS databases. For each urinary BPA value, the concentra-
tion (ng/ml) was combined with an estimated 24-h urinary output volume
(ml) to estimate daily BPA excretion (ng/day), which is assumed to be the
same as the daily intake. The daily intake for each individual was divided
by that individual’s body weight to give daily intake adjusted for body
weight (ng/kg-day) (Eq. 1). As body weights for the United States are
generally higher than those for Canadians,
5 intake, which includes an
adjustment for body weight, is a more informative measure of comparative
exposure than urinary BPA; intakes also allow for comparison with health-
based guidance values such as reference doses (RfDs) and tolerable daily
intakes (TDIs).
UrinaryBPAðng=mlÞ urinaryoutputðml=dayÞ=bodyweightðkgÞ
¼ ngBPA=kg-day ð1Þ
Since 24-h urinary output data were not collected as part of NHANES or
CHMS, generic values (given in,
3,4) describing typical urinary output
based on age and gender were used to estimate total daily BPA excretion
in nanograms. The urinary BPA data were used to represent daily
intake because excretion of BPA (parent and metabolite) into urine is
essentially complete in 24h.
6 Volume-based urinary BPA data (ng/ml
urine), rather than creatinine-adjusted BPA data, were used (the rationale
is described in
3,4).
Various researchers have explored the issue of intra-individual variability
in urinary BPA measures and while this introduces uncertainty in
population estimates of BPA intake, Ye et al.
7 concluded ‘‘ywhen the
population investigated is sufﬁciently large and samples are randomly
collected relative to meal ingestion times and bladder emptying times, the
single spot-sampling approach may adequately reﬂect the average
exposure of the population to BPA.’’ Further, Mahalingaiah et al.
8 stated
that ‘‘despite within-person variability in urinary BPA concentrations, a
single sample is predictive of long-term exposure (over weeks and
months).’’ LaKind and Naiman
3 concluded that NHANES cross-sectional
data provide a reasonable reference range for single day exposures and for
estimating average population exposures (and therefore intakes).
Distributions of intakes representative of the US and Canadian
populations were determined for all participants 6- -79 years, by gender
and age groups (6- -11, 12- -19, 20- -39, 40--59, and 60- -79 years). This
method differs slightly from past methodology: NHANES includes
individuals over the age of 79, and previous estimates of intakes included
these individuals. Since the age cutoff for CHMS is 79 years, the NHANES
database was truncated at 79 years for consistency. The total numbers of
respondents with all necessary data for estimating daily BPA intake were
2467 for NHANES and 5472 for CHMS.
Calculations of point estimates and conﬁdence intervals (CIs) for the
geometric mean intakes and intake percentiles for the US population were
carried out in the R platform,
9 using the R survey package.
10 To estimate
various population (and population subgroup) intake quantities such as
means or percentiles, weighted means and percentiles were calculated
using NHANES 2007--2008 2-year weights provided by CDC.
11 CIs for
percentiles were calculated using the survey package’s implementation of
Woodruff’s
12 method. Analysis of CHMS data was performed using SAS
version 9.2 (SAS Institute, Cary, NC, USA, 2003) and SUDAAN version 10
(RTI International, Research Triangle Park, NC, USA, 2008). Geometric
means, selected percentiles and corresponding CIs overall and by
population subgroups were calculated using the bootstrap technique;
the degrees of freedom were speciﬁed in the software as degrees of
freedom¼11 to account for the complex survey design.
2 A comparison of
the statistical methods used for NHANES and CHMS data was conducted;
the two methods yielded the same estimated intakes.
For measures below the limit of detection (LOD), CHMS assigns a value
of LOD/2; NHANES assigns a value of LOD/sq rt 2. For consistency between
the US and Canada, we elected to assign a value of LOD/2 for
measurements below the LOD in both data sets. However, we also
evaluated the impact on urinary BPA geometric means with using LOD/2
(CHMS) or LOD/sq rt 2 (NHANES).
Survey Methodology Comparison
Differences in the NHANES and CHMS methods related to population
characteristics, urine collection, analytical methods, and data reporting
were evaluated using information from the literature, statistical investigations,
and inter-laboratory comparisons. Survey method information was derived
from NHANES documentation (http://www.cdc.gov/nchs/nhanes/nhanes
2007--2008/datadoc_changes_0708.htm) and from CHMS reports.
2,13,14
As a result of the short physiologic clearance time for BPA (half-life
of o2h;
15), if the preponderance of BPA exposure is via the diet, then
a longer fasting time should correlate with lower urinary BPA levels. Thus,
systematic differences in either fasting times or adherence rates between
surveys could hinder the comparison of results. To test this, a correlation
test between fasting time and log urinary BPA was conducted by age
groups.
To explore the possibility of analytical bias between CDC and INSPQ (the
Institut Nationale de Sante ´ Publique du Que ´bec; the laboratory that
analyzed samples as part of the CHMS), data from two sets of proﬁciency
testing materials (PTMs) were evaluated. Both laboratories assessed PTMs
for urinary BPA from the Arctic Monitoring and Assessment Program INSPQ
ring test and the German External Quality Assessment Scheme for Analyses
in Biological Materials (G-EQUAS). In each of these programs, registered
participants received a set of two to three samples twice a year. Each
laboratory returned its analytical results to the program and received a
report showing the reliability of its results. Although the proﬁciency testing
took place during 2010- -2011, after NHANES 2007- -2008 and CHMS 2007- -
2009 were completed, these data were used as there are no data from
actual urine samples with which to assess analytical bias.
RESULTS
Comparison of Urinary BPA and Intakes in the US and Canada
Urinary BPA levels in Canada were statistically signiﬁcantly lower
than in the US for all age/gender groupings (Tables 1 and 2). In
general, body weights for Canadians are lower than in the United
States (Table 3), so for equivalent urinary BPA levels for US and
Canadian individuals, intakes for Canadians would be higher.
Despite the lower Canadian body weights, BPA intakes are
statistically signiﬁcantly lower in Canada as compared with the
US for all age/gender groupings (Tables 4 and 5).
Comparison of CHMS and NHANES Methods
The following methodological aspects and their potential impact
on spot urinary BPA levels are described below: urine collection
and population characteristics (Table 6), analytical procedures
(Table 7), and data reporting.
Urine Collection and Population Characteristics
Urine collection. The CHMS performed ﬁeld blank testing with
distilled water at all sites to account for baseline contamination
from the site environment, collection materials, and transport
method. The ﬁeld blank procedures mimicked all the procedures
of the survey samples including the urine collection, handling,
storage, shipping, and analysis. After adjustment for reagent
blanks, ﬁeld blank BPA data indicated no BPA contamination.
14
NHANES does not use ﬁeld blanks but rather tests all new
collection materials to ensure no contamination exists. CHMS
requested midstream urine samples; NHANES did not specify
portion of urine stream to be sampled.
Collection timeframe. Although CHMS and NHANES samples used
in this study were not collected over identical time periods (Table 6),
there was only a 2-month shift in sampling times between the two
surveys, which is not expected to inﬂuence overall results.
Population sampled. In NHANES, urinary BPA data were
available for ages 6 years and older (no upper age cutoff), while
in CHMS the age range was 6 to 79 years. For the CHMS sample
with urinary BPA data, 81.2% of the respondents were white and
o3.9% were black while for the NHANES 40% of the participants
Comparing US/Canadian biomonitoring surveys
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sample weights applied to produce an unbiased national esti-
mate) (http://www.cdc.gov/nchs/tutorials/nhanes/SurveyDesign/
SampleDesign/Info1.htm). In the United States, blacks had higher
urinary BPA levels (geometric mean of 2.6ng/ml, 95% CIs: 2.4, 2.9)
compared with whites (geometric mean of 2.1ng/ml, 95% CIs: 1.9,
2.3). Owing to the small sample size, the urinary BPA levels of black
Canadians could not be assessed. The median urinary BPA (95%
CIs) for whites in the United States was 2.1ng/ml (1.8, 2.3), which
was essentially the same as the median for the overall US
population. For whites in Canada, the median urinary BPA (95%
CIs) was 1.3ng/ml (1.2--1.5), also the same as for the overall
population.
Fasting. For NHANES, respondents aged 12 years and older
were instructed to fast for 9h (but not 416h) before their
morning appointment. Fasting was not required for respondents
o12 years of age and for those with afternoon or evening
appointments (http://www.cdc.gov/nchs/data/nhanes/nhanes_07_08/
HouseholdInterviewer_07.pdf). For CHMS, respondents were instruc-
t e dt of a s tf o r1 2hb e f o r et h em o r n i n ga p p o i n t m e n to rf o r2hb e f o r e
an afternoon or evening appointment.
13 I n f o r m a t i o no nh o u r ss i n c e
food/drink was consumed before the appointment was recorded for
each respondent.
In this study, overall, no association between fasting time and
urinary BPA level was found for either survey. For NHANES,
younger respondents (6- to 19-year olds) had shorter fasting times
(median of 2h for 6- to 11-year olds and 4h for 12- to 19-year
olds) compared with older participants (median of 5h for 20- to
79-year olds) and had higher urinary BPA levels (Table 2).
Analytical Procedures
Major differences between analytical procedures in the US and
Canada include the use of liquid versus gas chromatographic
techniques and the use of enzymes during the hydrolysis stage
Table 1. Urinary BPA concentrations (ng/ml) for Canada (CHMS 2007--2009) and the US (NHANES 2007- -2008) for participants 6 to 79 years of age
and by gender.
Urinary BPA (ng/ml)
a
All Male Female
US Canada US Canada US Canada
25th % 1.1 (1.0, 1.2) 0.6 (0.5, 0.7) 1.1 (1.1, 1.3) 0.7 (0.6, 0.8) 1.0 (0.8, 1.1) 0.5 (0.4, 0.6)
50th % 2.1 (1.9, 2.3) 1.3 (1.2, 1.5) 2.1 (1.9, 2.4) 1.4 (1.3, 1.6) 2.1 (1.9, 2.3) 1.2 (1.0, 1.4)
75th % 4.1 (3.7, 4.6) 2.6 (2.3, 2.8) 4.0 (3.6, 4.6) 2.7 (2.3, 3.0) 4.1 (3.8, 4.5) 2.4 (2.1, 2.8)
90th % 7.8 (6.9, 8.7) 4.6 (4.1, 5.2) 7.9 (6.9, 9.3) 4.5 (3.9, 5.0) 7.7 (6.9, 8.6) 4.9 (4.3, 5.6)
Mean 4.1 (3.5, 4.6) 2.3 (2.1, 2.5) 4.2 (3.4, 5.0) 2.4 (2.1, 2.8) 3.9 (3.3, 4.5) 2.2 (1.9, 2.5)
Geometric mean 2.1 (1.9, 2.3) 1.2 (1.1, 1.2) 2.2 (2.0, 2.4) 1.3 (1.2, 1.4) 2.0 (1.8, 2.2) 1.0 (0.9, 1.2)
Count 2489 5476 1238 2659 1251 2817
aAssigning a value of LOD/2 for measures below the LOD; 95% CIs in parentheses.
Table 2. Urinary BPA concentrations (ng/ml) by age group for Canada (CHMS 2007- -2009) and the US (NHANES 2007- -2008).
Urinary BPA (ng/ml)
a
Age 6- -11 years Age 12- -19 years Age 20- -39 years Age 40- -59 years Age 60- -79 years
US Canada US Canada US Canada US Canada US Canada
25th % 1.4 (1.2, 1.5) 0.7 (0.6, 0.8) 1.3 (1.1, 1.5) 0.8 (0.6, 1.0) 1.3 (1.2, 1.5) 0.7 (0.5, 0.9) 0.8 (0.7, 1.0) 0.5 (0.4, 0.6) 0.8 (0.7, 0.9) 0.5 (0.4, 0.5)
50th % 2.3 (2.0, 3.0) 1.4 (1.2, 1.6) 2.3 (2.1, 2.6) 1.7 (1.4, 2.0) 2.4 (2.2, 2.7) 1.5 (1.3, 1.7) 1.8 (1.5, 2.2) 1.3 (1.1, 1.4) 1.5 (1.2, 1.8) 1.0 (0.8, 1.2)
75th % 4.4 (3.8, 5.3) 2.7 (2.3, 3.0) 4.4 (3.9, 5.5) 3.0 (2.3, 3.7) 4.7 (4.0, 5.7) 2.8 (2.5, 3.2) 3.8 (3.1, 4.6) 2.5 (2.1, 2.9) 3.0 (2.6, 3.4) 1.9 (1.6, 2.2)
90th % 7.0 (6.7, 9.4) 4.5 (3.9, 5.1) 9.6 (7.4, 11.8) 5.9 (4.8, 7.0) 8.5 (6.9, 11.6) 4.8 (4.2, 5.4) 7.3 (5.8, 8.2) 4.4 (3.5, 5.3) 6.5 (4.7, 9.9) 3.8 (3.3, 4.2)
Mean 4.2 (3.3, 5.1) 2.6 (2.1, 3.1) 4.2 (3.3, 5.0) 2.6 (2.2, 3.1) 4.3 (3.6, 5.0) 2.7 (2.2, 3.2) 4.2 (2.9, 5.5) 2.1 (1.8, 2.4) 3.1 (2.4, 3.7) 1.7 (1.5, 1.9)
Geometric
mean
2.5 (2.2, 2.7) 1.3 (1.2, 1.5) 2.4 (2.2, 2.8) 1.5 (1.3, 1.8) 2.5 (2.2, 2.8) 1.3 (1.2, 1.5) 1.8 (1.7, 2.0) 1.0 (1.0, 1.1) 1.6 (1.4, 1.8) 0.9 (0.8, 1.0)
Count 389 1031 401 980 592 1165 592 1219 515 1081
aAssigning a value of LOD/2 for measures below the LOD; 95% CIs in parentheses.
Table 3. Comparison of mean body weights (kg) by age group
and gender for the US (NHANES 2007- -2008) and Canada (CHMS
2007- -2009).
Gender Age group
(years)
Canada: mean body
weight (kg)
US: mean body
weight (kg)
Both 6- -79 72.8
a 76.3
Male 6- -79 78.8 81.9
6- -11 33.5 36.7
12- -19 66.3 69.8
20- -39 82.6 87.9
40- -59 87.0 90.8
60- -79 84.3
a 90.1
Female 6- -79 66.7 70.7
6- -11 33.3 33.8
12- -19 59.9 61.5
20- -39 69.1
a 76.0
40- -59 71.4
a 77.4
60- -79 71.4 74.5
aSigniﬁcantly different from the United States (conﬁdence interval overlap).
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use of different analytical methods is less important than whether
those methods produce comparable results
18; both INSPQ and
CDC use an internal calibration standard (
13C-labeled BPA) to
compensate for some of the analytical differences. However,
utilization of enzymes with different efﬁciencies cannot be
completely compensated for by internal standardization and
could generate bias in the overall results.
Seven samples from the two proﬁciency programs were
analyzed by both laboratories (Table 8). Individual laboratory data
are not provided here in order to protect conﬁdentiality of the
participating laboratories’ identities in these proﬁciency testing
programs. For CDC and INSPQ, only their mean urinary BPA
concentration from the seven PTMs is compared with a consensus
concentration; the consensus concentration is deﬁned as the
mean of the seven median values from all reporting laboratories
(Table 8). The results are as follows (CDC value was provided by
the NCEH laboratory for this comparison):
1. Consensus PTM mean urinary BPA concentration 4.77mg/l
2. INSPQ PTM mean urinary BPA concentration 4.98mg/l
3. CDC PTM mean urinary BPA concentration 5.81mg/l
The INSPQ mean concentration is 14% lower than that for CDC.
As compared with the consensus value, INSPQ and CDC results are
4% and 22% higher, respectively. Considering the differences in
analytical methodology and the complicated nature of sample
preparation, these differences are minor. The proﬁciency testing
was conducted using samples with a urinary BPA concentration of
approximately 5mg/l. It is not known how or whether the percent
difference observed between laboratories would change if the
PTM concentrations were closer to the LOD.
Data Reporting
For urinary BPA, 151 respondents for NHANES and 507
respondents for CHMS had values oLOD (6.1% and 9.3%,
respectively). The difference in the method of reporting values
oLOD did not substantially affect urinary BPA concentrations
(e.g., for NHANES, considering all participants, there was no
difference in the geometric mean value for urinary BPA using
LOD/2 or LOD/sq rt 2 (2.1ng/ml, CIs:1.9, 2.3)).
Both the US and Canada set the LOD at 3 SD and limit of
quantitation (LOQ) at 10 SD of replicate analyses (5 or 10) of
samples with concentrations near the LOQ. Measurements with
concentrations between the LOD and the LOQ are reported as
above the LOD in the ﬁnal data sets in both surveys. Both
laboratories performed reagent blank checks but only INSPQ
found slightly higher results than LOD that had to be subtracted
from reported data. An assessment of whether this adjustment
could lead to a bias found a minimal impact on overall results and
no negative concentrations after blank subtraction indicating no
over-correction that could produce lower results.
DISCUSSION
Biomonitoring data for several chemicals are now available for two
neighboring countries --- the US and Canada --- providing
researchers with the opportunity to compare chemical concentra-
tions and develop hypotheses regarding exposures. Before these
types of comparative assessments are conducted, researchers
should be aware that the CHMS and NHANES are not identical;
similarities and differences in the surveys should be assessed
before performing comparisons. We used BPA as a case study to
explore factors that might bias comparisons between surveys.
Speciﬁcally, we focused on urine collection methods, population
characteristics, analytical procedures, and data reporting methods.
We discuss each of these here.
Urine Collection and Population Characteristics
Urine collection. One difference that could impact comparability
of results is the use of ﬁeld blanks by CHMS but not by NHANES.
BPA in the body is rapidly metabolized by the liver to conjugated
BPA and is excreted as essentially completely conjugated BPA. To
analyze urinary BPA, the BPA conjugates are converted back to
free, or parent, BPA via digestion with enzymes. Thus, laboratory
measurements are of free BPA and cannot distinguish between
environmental BPA, which is in the free form, and physiologic BPA,
also in the free form after digestion of the urine. Without ﬁeld
blanks, it is not possible to determine whether sample contam-
ination from environmental BPA sources or collection and storage
devices impact urine sample measurements.
19 In the CHMS, ﬁeld
blanks were used to quantify contamination; however, no
comparable ﬁeld blank data are available for the NHANES
program. One possible source of contamination of urine samples
is dust, which was detected, for example, in 95% of dust samples
in the United States, albeit at very low levels (o0.5 to 10,200ng/g;
mean 843ng/g; median 422ng/g).
20 To date, there is no evidence
that environmental levels are high enough to substantially impact
overall levels in urine, although this could conceivably be a source
of bias in studies of low levels of parent BPA in serum.
19
Population characteristics. Certain aspects of the sample
populations in the CHMS and NHANES could impact comparison
of biomonitoring results. First, the upper age cutoff differs for the
two surveys. NHANES includes individuals ages 6 years and older,
while CHMS has an upper age cutoff of 79 years of age. For urinary
Table 4. BPA intakes (ng/kg-day) for Canada (CHMS 2007- -2009) and the US (NHANES 2007- -2008).
BPA intakes (ng/kg-day)
a
All Male Female
US Canada US Canada US Canada
25th % 18.3 (16.2, 20.0) 10.8 (9.4, 12.2) 20.9 (18.5, 23.4) 13.6 (11.4, 15.8) 14.6 (13.6, 16.5) 8.4 (7.2, 9.6)
50th % 37.3 (34.0, 40.2) 24.3 (21.2, 26.8) 39.4 (35.6, 43.8) 27.6 (24.4, 30.8) 35.0 (31.6, 37.4) 21.1 (18.3, 23.9)
75th % 70.3 (63.6, 79.7) 47.0 (41.6, 52.4) 73.3 (65.6, 88.6) 51.4 (43.2, 59.6) 68.4 (60.7, 76.2) 43.9 (38.1, 49.7)
90th % 140.3 (126.6, 159.0) 89.2 (79.5, 98.8) 144.3 (120.4, 192.1) 90.7 (79.4, 102.1) 135.0 (124.5, 155.8) 88.0 (75.9, 100.2)
Mean 73.4 (62.5, 84.2) 43.3 (39.3, 47.3) 78.7 (62.4, 95.0) 46.4 (40.4, 52.3) 68.2 (55.7, 80.7) 40.2 (35.5, 44.9)
Geometric mean 36.9 (34.1, 40.0) 21.4 (20.0, 22.9) 40.5 (36.7, 44.6) 24.6 (23.0, 26.4) 33.8 (31.2, 36.6) 18.5 (16.9, 20.3)
Count 2467 5472 1227 2657 1240 2815
aIntakes are for all participants 6 to 79 years of age and by gender (assigning a value of LOD/2 for measures below the LOD; 95% CIs in parentheses).
Comparing US/Canadian biomonitoring surveys
LaKind et al
222
Journal of Exposure Science and Environmental Epidemiology (2012), 219- -226 & 2012 Macmillan Publishers LimitedBPA measurements, this is unlikely to hinder inter-survey
comparisons; limiting the NHANES population to ages 6 to 79
years resulted in the removal from the database of only 134
individuals and did not change the geometric mean urinary BPA
concentration for the overall population. However, for other
chemicals, attention should be paid to the effect of different age-
based exclusion criteria. The effect of exclusion should be tested
on case-by-case basis and is likely especially important for
chemicals with age-dependent biomonitoring data results such
as lipophilic, bioaccumulative compounds.
21 Second, body
weights for the Canadian population are lower than those for
the United States, which for equivalent urinary BPA levels would
produce higher intake estimates. Third, researchers need to
recognize differences in race and ethnicity between the popula-
tions in the US and Canada. The Canadian population has a far
smaller proportion of blacks than whites compared with the US
population. Given that urinary BPA levels in blacks were
statistically signiﬁcantly higher than for whites, this inter-country
difference in population make-up raises potentially important
questions for urinary BPA comparisons --- as well as comparison of
other biomonitored chemicals --- between countries. For example,
how does the difference in racial make-up of the two populations
affect distributions of concentrations in the overall populations? In
addition, is the observed difference in urinary BPA concentrations
between races due to factors related to diet and/or other lifestyle
variables, or is it due to differences in the way whites and blacks
metabolize certain chemicals? Racial variations in enzymes that
catalyze the sulfate conjugation of drugs, other xenobiotics,
neurotransmitters, and hormones have been observed.
22 Given
the difference in racial/ethnic make-up of the CHMS and NHANES
populations, exploration of this topic is warranted.
Fasting times. As a result of the short physiologic half-life of BPA
and the assumption that the preponderance of BPA exposure is
via diet, the duration of fasting before urine sample collection
could have a substantial impact on measured urinary BPA levels.
Systematic differences in fasting times between countries could
therefore hinder the ability to directly compare urinary BPA data
from the CHMS and NHANES. We examined this by comparing
NHANES and CHMS fasting times to log urinary BPA concentra-
tions and found essentially no correlation. A lack of correlation
between fasting time and urinary BPA was also reported by Braun
et al.
23 Several factors could contribute to this result. First, non-
dietary sources may contribute to BPA exposure. Rudel et al.
24
found that dietary changes to reduce exposure to food packaging
resulted in a 66% decrease in urinary BPA levels, suggesting that
diet contributes to some, but possibly not all BPA exposure.
Alternatively, it is possible that incorrect participant reporting of
fasting times could contribute to the observed lack of correlation
between fasting time and urinary BPA concentration. To address
this, improved data on fasting adherence and reporting in future
studies are needed. The impact of variations in --- and adherence
to --- fasting time in NHANES and CHMS should be examined on a
chemical-by-chemical basis when comparing biomonitoring data
across countries. Finally, there are most certainly differences in
participant exposures to BPA in terms of both timing and amount,
which hinder our ability to evaluate the effect of fasting on urinary
BPA concentrations (e.g., a large intake coupled with a long fasting
time might yield a similar urinary BPA level as a small intake
coupled with a short fasting time); the importance of this issue
cannot be quantiﬁed without additional research.
Analytical Methods
Results from the proﬁciency testing revealed that CDC’s results
were approximately 14% higher, on average, than those for INSPQ.
It is important to note that this difference is based on a small
number (N¼7) of samples and that individual data for the
samples are not available to further assess consistency. However,
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related to the efﬁciency of the enzymes used to deconjugate the
conjugated BPA in urine. CDC and INSPQ utilize different enzymes
for deconjugating BPA conjugates; the enzyme used by CDC may
be more efﬁcient at breaking the sulfonate conjugate. Preliminary
investigations conducted by INSPQ using unspiked urine samples
to compare enzyme efﬁciency revealed that CDC’s enzymatic
conditions produce concentrations that are 10% higher than
INSPQ’s concentrations (unpublished data), suggesting that
enzyme efﬁciency is the major contributor to the analytical bias.
In general, inter-laboratory proﬁciency testing is an important
step that should be conducted for any chemical for which inter-
survey comparisons are attempted. However, for BPA, it is noted
that although there is a slight positive bias, on average, between
results produced by the CDC compared with INSPQ, and
recognizing the limitations of the available inter-laboratory
proﬁciency testing data, analytical method bias does not appear
to fully explain the difference in the results of urinary BPA
concentrations between the American and Canadian populations.
Data Reporting
Two data reporting issues were identiﬁed that should be
considered when comparing CHMS and NHANES biomonitoring
data. The ﬁrst relates to differences in limits of detection and the
method for reporting measures below the LOD. For urinary BPA,
although the LODs and the method for reporting measures below
the LOD differ, there were too few non-detects for this to
substantially impact overall urinary BPA levels. For chemicals with
high frequencies of non-detects (e.g., dioxins), consideration of
this difference in data reporting will be more important.
25
The second issue concerns temporal variability in chemical
concentration and frequency of reporting. There are four time-
frames in the United States for which there are adult population
Table 6. Comparison of relevant aspects of the CHMS and NHANES programs and population characteristics.
14,16
Parameter Canada CHMS US NHANES
Age (years) for BPA measures 6--79 6 and older
Date range of sample collection 3/2007- -2/2009 1/2007- -12/2008
Representation for CHMS and NHANES 96.3% of population Survey sample selected to represent the US population of all
ages. To produce reliable statistics, NHANES over-samples
persons 60 and older, African Americans, and Hispanics.
Excluded Full-time members of Canadian
Forces, residents of Crown lands,
Indian reserves, institutions, and
certain remote regions
Non-civilian and institutionalized populations.
N for urinary BPA analysis (N for BPA
intake analysis)
a
5476 (5472) 2489 (2467)
Field blanks Field blanks were included at all
15 sites.
None.
Data reporting for urinary BPA
measures below LOD
LOD/2 (0.2/2) LOD/sq rt 2 (0.4/sq rt 2)
Fasting 10--12h for morning appointments and
2h for afternoon and evening
appointments.
No fasting required for those under the age of 12 years or for
those with afternoon or evening appointments. Nine hours
for those 12 years and over with morning appointments.
aSample size for estimates of intake is smaller than the total number of samples analyzed for BPA because data needed to estimate intake (e.g., body weight)
were not available for all participants.
Table 7. Analytical method comparison for urinary BPA: INSPQ (Canada) and CDC (the US).
Parameter INSPQ method: 2007- -2009 CDC method: 2007- -2008
Hydrolysis
a Enzyme glucuronidase HP-2, pH¼5, 3h at 371C Enzyme glucuronidase H-1, pH¼5, 4h at 371C
Derivatization Pentaﬂuorobenzyl bromide
2 hours 701C
None
Extraction Liquid- -liquid On-line solid phase
Internal standardization BPA analog carbon 13 BPA analog carbon 13
Calibration curve 7 Levels (0.2- -50mg/l)
Spiked in urine
9 Levels (0.1- -100mg/l) in methanol/0.1 M formic acid; standards
also go through the online-SPE system
Instrumentation GC-MS-MS (Waters Quattro micro GC) HPLC-MS-MS (Agilent-API 4000)
Mass spectrometry
detection
Tandem mass spectrometry
Negative Chemical ionization with methane (NCI)
Tandem mass spectrometry
Negative-ion atmospheric pressure chemical ionization (APCI)
Sensitivity (LOD) 0.2mg/l, 100ml Urine used for method 0.4mg/l, 100ml Urine used for method
LOQ 0.82mg/l 1.2mg/l
Internal quality control Low QC 0.8mg/l±18%
High QC 28mg/l±5%
Low QC 2.8mg/l±5.9%
High QC 10.0mg/l±4.8%
Reagent blank 2 Reagent blanks per 40 samples.
BPA level detected: 0.2±0.2mg/l
2 Reagent blanks per 50 samples. No BPA detected
aCDC: b-glucuronidase type H-1 is from Helix pomatia, Sigma Aldrich (G0751); glucuronidase activity Z300,000 units; sulfatase activity Z10,000 units.
INSPQ: b-glucuronidase type HP-2 is from Helix pomatia, Sigma Aldrich (G7017); glucuronidase activity Z100,000 units/ml; sulfatase activity Z7500 units/ml.
More detailed methods are available for CDC in Ye et al.
17 and for INSPQ at: Canadian Health Measures Survey (www.statcan.gc.ca/chms).
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temporal trend for urinary BPA in the United States reveals
variability that is not likely due to overall changes in exposure as
there is no evidence of major changes in use of BPA over this time
period
4 nor is the variability because of changes in analytical
methodology (Calafat AM, personal communication). Research on
temporal variability in individual urinary BPA levels
7 suggests the
possibility that the short physiologic half-life of BPA coupled with
variations in day-to-day individual exposure could be responsible
for some of the variability observed in Figure 1. Additional years’
worth of data may be required to observe actual trends in urinary
BPA levels. The temporal variability further suggests that
comparing urinary BPA levels across countries without taking into
account year-to-year variability is inappropriate. In fact, the
geometric mean concentration for the CHMS 2007--2009 urinary
BPA data (1.1ng/ml, 95% CIs: 1.0, 1.2) is comparable to the
geometric mean concentrations for the NHANES data from 1988
to 1994 (1.3ng/ml).
26 For chemicals with long half-lives, less
extensive temporal data reporting may be required for inter-
survey comparisons.
Two relationships have remained relatively consistent in the US
and Canada: the overall relationships between gender and age
and urinary BPA. In all data sets except one, males had higher
urinary BPA levels than females (in NHANES 2007--2008, median
levels were the same for males and females) (Figure 2). In general,
younger people have higher urinary BPA levels than older people,
although the relationship between the 6- to 11-year age group
and the 12- to 19-year age group has ﬂuctuated depending on the
timeframe examined (Figure 2).
3,4
CONCLUSIONS
We identiﬁed several dissimilar methodologic aspects of the
NHANES and CHMS. The differences assessed in this study appear
to have minimal impact on the interpretation of comparative
urinary spot BPA measures and BPA intake from the two surveys.
An earlier review of methodologic differences in measurements of
dioxins in breast milk highlighted the importance of evaluating
study design before comparing data sets from different research
groups.
27 We recommend that before developing hypotheses
regarding comparisons of biomonitoring data between surveys
from different countries, a thorough review of methodologic
aspects that might impact biomonitoring results be conducted.
We further recognize the ongoing controversy regarding the
interpretation of studies of toxicity of BPA but note that health-
based guidelines are available with which to compare population-
based BPA intakes estimated from the CHMS and NHANES data. A
TDI of 50mg/kg-day (50,000ng/kg-day) has been established by
the European Food Safety Authority
28; the same value is used by
the US Environmental Protection Agency as an RfD.
29 A provisional
TDI of 25mg/kg bw-day (25,000ng/kg-day) was established by
Health Canada.
30 Based on the intakes estimated for US and
Canadian populations (Tables 4 and 5), regardless of age or
gender, all intakes are well below the health-based guidance
values set by the US, Canada, and the European Food Safety
Authority. For example, the 90
th% intakes for 12- to 19-year olds,
Table 8. Description of proﬁciency testing materials used for inter-
laboratory comparisons of analytical methods.
Sample ID Program (number
of participants)
Median urinary BPA
concentration (mg/l)
44(14A) German EQUAS (8) 3.3
44 (14B) German EQUAS (8) 11.5
BPA-2010-07 AMAP-INSPQ (5) 2.9
BPA-2010-08 AMAP-INSPQ (5) 4.8
BPA-2010-09 AMAP-INSPQ (5) 0.9
46A (14A) German EQUAS (8) 3.2
46B (14B) German EQUAS (8) 6.8
Consensus value (mean of median values from each of the seven samples):
4.77mg/l.
Figure 1. Adult urinary bisphenol A (BPA) levels (mg/l, geometric
mean and 95% CIs) in the US and Canada. Data for 1988--1994 are
from
26 (no conﬁdence intervals were given; ages 18 and older). For
the remaining years, data are from the online Centers for Disease
Control and Prevention data tables for urinary BPA in adults 20 years
and older (limit of detection (LOD)/sq rt 2) (http://www.cdc.gov/
exposurereport/data_tables/URXBPH_DataTables.html) and from
Canadian Health Measures Survey data for adults 20 years and older
(truncated at age 79 years and using LOD/2).
Figure 2. Urinary bisphenol A (BPA) estimates (ng/ml, median and
95% conﬁdence intervals) in the US (National Health and Nutrition
Examination Survey 2003--2004, 2005--2006, and 2007--2008) and
Canada (Canadian Health Measures Survey 2007--2009) for men and
women and for several age groups over four timeframes (using limit
of detection (LOD)/2 for measures below the LOD).
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both countries, were more than two orders of magnitude below
the TDI for Canada and the RfD for the US.
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